MyD88 (N-Term) Rabbit Monoclonal Antibody

MyD88 is an adaptor protein involved in the innate immune response.{58195,58196} It is composed of an N-terminal death domain, intermediate domain, and C-terminal toll-interleukin-1 receptor (TIR) domain.{58195} It is expressed in both myeloid and non-myeloid tissues, and its expression can be induced by immune-related factors, such as IL-6, LPS, and IFNs.{58196} As an adaptor protein, the TIR domain of MyD88 interacts with the TIR domain of toll-like receptor 1 (TLR1), -2, -4, -5, and -6, and IL-1 receptor (IL-1R) at the plasma membrane and TLR7, -8, and -9 at the endosomal membrane, while the MyD88 death domain interacts with IL-1R-associated kinases (IRAKs).{58195,58199} In this way, MyD88 translates signals from TLRs and IL-1Rs to IRAKs, inducing signaling that leads to activation of NF-?B and subsequent cytokine production, as well as MAPK signaling.{58195,58196} MyD88 is associated with inflammatory carcinogenesis but is also associated with protection from oncogenic pathogens.{58197} Mice deficient for Myd88 are protected from endotoxic shock induced by the TLR4 agonist LPS but have an increased susceptibility to bacterial pathogens and parasites.{58195} A leucine-to-proline mutation at position 265 of MYD88, within the TIR domain, is associated with certain cancers, including Waldenström’s macroglobulinemia and activated B cell diffuse large B cell lymphomas.{58198} Cayman’s MyD88 (N-Term) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.